1200 Leveraging the immunocompetent Vk*MYChCRBN model of multiple myeloma to determine and overcome T cell engager antibody resistance mechanisms

• Natalie Bezman,
• Erin W Meermeier,
• Caleb Stein,
• Meaghen Sharik,
• Megan Du,
• Chang-Xin Shi,
• Yuan Xiao Zhu,
• Keith Abayasiriwardana,
• Timothy Fisher,
• Bas Baaten,
• Kristin Bompiani-Myers,
• P Leif Bergsagel,
• Marta Chesi

Affiliations

Natalie Bezman

2Pfizer Inc., San Diego, CA, USA

Erin W Meermeier

1Mayo Clinic, Scottsdale, AZ, USA

Caleb Stein

1Mayo Clinic, Scottsdale, AZ, USA

Meaghen Sharik

1Mayo Clinic, Scottsdale, AZ, USA

Megan Du

1Mayo Clinic, Scottsdale, AZ, USA

Chang-Xin Shi

1Mayo Clinic, Scottsdale, AZ, USA

Yuan Xiao Zhu

1Mayo Clinic, Scottsdale, AZ, USA

Keith Abayasiriwardana

2Pfizer Inc., San Diego, CA, USA

Timothy Fisher

2Pfizer Inc., San Diego, CA, USA

Bas Baaten

2Pfizer Inc., San Diego, CA, USA

Kristin Bompiani-Myers

2Pfizer Inc., San Diego, CA, USA

P Leif Bergsagel

1Mayo Clinic, Scottsdale, AZ, USA

Marta Chesi

1Mayo Clinic, Scottsdale, AZ, USA